Search / Trial NCT00001512

Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines

Launched by NATIONAL CANCER INSTITUTE (NCI) · Nov 3, 1999

Trial Information

Current as of December 05, 2024

Completed

Keywords

Pro Mace Chemotherapy Indolent Lymphoma Anti Idiotype Antibody Gm Csf B Cell Lymphoma

ClinConnect Summary

The idiotype of the immunoglobulin on a given B cell malignancy (Id) can serve as a clonal marker, and a previous pilot study in lymphoma patients has demonstrated that autologous Id protein can be formulated into an immunogenic, tumor specific antigen by conjugation to a carrier protein (KLH) and administration with an emulsion-based adjuvant. The goals of vaccine development in the current study are to develop vaccines: 1) with improved potency and 2) which are more effective at inducing cell-mediated immune responses. The selection of GM-CSF as the immunological "adjuvant" is a direct ex...

Gender

ALL

Eligibility criteria

  • * INCLUSION CRITERIA:
  • Patients must meet all of the following eligibility criteria.
  • Tissue diagnosis of: follicular small cleaved cell, or follicular mixed lymphoma with surface IgM, IgG or IgA phenotype with a monoclonal heavy and light chain. Pathology slides must be submitted to the NIH Pathology Department for review.
  • Stage III or IV lymphoma.
  • Only previously untreated patients are eligible.
  • Previous treatment with radiation alone (less than TBI) is permissible.
  • A single peripheral lymph node of at least 2 cm size accessible for biopsy/harvest.
  • Karnofsky status greater than or equal to 70 percent.
  • Life expectancy of greater than 1 year.
  • Serum creatinine less than or equal to 1.5 mg per dl unless felt to be secondary to lymphoma.
  • Bilirubin less than or equal to 1.5 mg/dl unless felt to be secondary to lymphoma or Gilbert's disease. SGOT/SGPT less than or equal to 3.5 times upper limit of normal.
  • Ability to give informed consent. Ability to return to clinic for adequate follow-up for the period that the protocol requires.
  • EXCLUSION CRITERIA:
  • Prior total body irradiation.
  • Presence of antibodies to HIV, hepatitis B surface antigen or other active infectious process.
  • Pregnancy or lactation. Fertile men and women must plan to use effective contraception. A beta-HCG level will be obtained in women of child-bearing potential.
  • Patients with previous or concomitant malignancy, regardless of site, except curatively treated squamous or basal cell carcinoma of the skin, or effectively treated carcinoma in situ of the cervix.
  • Patients unwilling to give informed consent.
  • Failure to meet any of the inclusion criteria.
  • Any medical or psychiatric condition that in the opinion of the protocol chairman would compromise the patient's ability to tolerate this treatment will be excluded from this protocol.
  • Patient with CNS lymphoma (current or previously treated) will not be eligible.

About National Cancer Institute (Nci)

The National Cancer Institute (NCI) is a prominent component of the National Institutes of Health (NIH), dedicated to advancing cancer research and improving patient outcomes through innovative clinical trials. As a leading sponsor of cancer-related studies, NCI focuses on facilitating the development of new therapies, enhancing prevention strategies, and understanding the biology of cancer. The institute collaborates with academic institutions, healthcare providers, and industry partners to conduct rigorous clinical trials that aim to translate scientific discoveries into effective treatments. NCI’s commitment to fostering a robust research environment supports the mission to eliminate cancer as a major health problem.

Locations

Bethesda, Maryland, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials